Can Eltrombopag/Eltrombopag be discontinued directly if it fails?

Eltrombopag/Eltrombopag (Eltrombopag) plays an important role in the treatment of chronic immune thrombocytopenia (ITP) and aplastic anemia, but in some patients there may be poor efficacy or delayed onset of action. For this group of people, whether the drug can be stopped directly is a common clinical treatment decision-making problem. In fact, as a targeted drug that gradually regulates the hematopoietic mechanism, the efficacy of eltrombopag is not immediate. Sudden discontinuation of the drug may bring potential risks and needs to be handled with caution.

First of all, it should be clear that the onset time of eltrombopag varies from person to person, and it generally requires continuous use for at least 2 to 4 weeks to observe a stable increase in platelets. Some patients may have delayed onset of action due to complex underlying conditions, active immune mechanisms, or poor bone marrow reserves. Therefore, there should be clear criteria for judging "ineffective", which is generally based on the lack of platelet response after 8 consecutive weeks of treatment at the standard dose, rather than a hasty assessment based on subjective feelings.

If it is confirmed to be ineffective after sufficient dosage and treatment, it is not recommended that the patient stop taking the medication on his own. The reason is that the regulation of platelet production involves a variety of feedback mechanisms, and sudden discontinuation of the drug may trigger "rebound platelet drop" and even the risk of bleeding. Especially in patients with chronic ITP whose condition is not stable, sudden interruption of treatment may cause more serious clinical deterioration.

In clinical practice, a gradual reduction transition strategy is usually adopted instead of directly discontinuing the drug. Even if the drug is not effective enough, it can be used alternately with other immunosuppressive drugs, splenectomy, or a combination of intravenous globulin to find a more suitable solution in multi-line treatment. In addition, drug-resistant or hyporesponsive individuals may have drug absorption problems or genetic polymorphisms. In this case, blood drug concentrations or drug metabolism genes can be checked to help determine the cause and avoid misjudgment that "the drug is ineffective."

Reference materials:https://go.drugbank.com/drugs/DB06210